ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics and technology company, and Biotheus Inc., a clinical-stage biotech specializing in biologics for oncology and inflammatory diseases, have announced the signing of a Material Transfer and Evaluation Agreement (MTEA). This agreement involves a Talem Therapeutics antibody, designed for the development of a bispecific treatment for solid tumors.
Under the MTEA, Biotheus will gain rights to evaluate the lead candidate, TATX-20, using Talem’s AI technology. The goal is to develop novel bispecific antibodies targeting hypoxic solid tumors. Talem Therapeutics, a subsidiary of ImmunoPrecise, will supply Biotheus with a specialized antibody to be integrated with Biotheus’ technology, aiming to create innovative cancer therapies. These bispecific antibodies are engineered to simultaneously target two different tumor markers, especially those in oxygen-deprived areas, offering potential advancements in cancer treatment.
The collaboration aims to accelerate the development of these promising therapies, ultimately identifying the best candidate for clinical trials. This could speed up the creation of new cancer treatments, addressing challenges in hard-to-treat tumor environments.
“We’re pleased to collaborate with ImmunoPrecise, a leader in AI-driven biotech,” said Xiaolin Liu, Co-Founder, Chairman, and CEO of Biotheus. “With our antibody expertise and ImmunoPrecise’s AI-powered molecules, we hope to develop first-in-class bispecific antibodies that could bring breakthrough treatments to cancer patients globally.”
ImmunoPrecise CEO Dr. Jennifer Bath shared her enthusiasm: “This agreement marks a strategic collaboration, combining our AI-enhanced antibody discovery technology with Biotheus’ bispecific engineering expertise. Together, we aim to accelerate the creation of innovative cancer treatments, potentially leading to breakthrough clinical outcomes.”
The transfer of this therapeutic asset is expected to advance the development of targeted treatments for solid tumors. Biotheus will evaluate TATX-20, and if successful, will continue developing bispecific antibodies, potentially leading to a new class of cancer therapies for hypoxic tumors resistant to current treatments.
